



Cite this: *Phys. Chem. Chem. Phys.*,  
2016, 18, 21590

# Effect of $\text{Zn}^{2+}$ ions on the assembly of amylin oligomers: insight into the molecular mechanisms†

Vered Wineman-Fisher<sup>ab</sup> and Yifat Miller<sup>\*ab</sup>

Amylin is an endocrine hormone and is a member of the family of amyloid peptides and proteins that emerge as potential scaffolds by self-assembly processes.  $\text{Zn}^{2+}$  ions can bind to amylin peptides to form self-assembled  $\text{Zn}^{2+}$ -amylin oligomers. In the current work the binding sites of  $\text{Zn}^{2+}$  ions in the self-assembled amylin oligomers at various concentrations of zinc have been investigated. Our results yield two conclusions. First, in the absence of  $\text{Zn}^{2+}$  ions polymorphic states (*i.e.* various classes of amylin oligomers) are obtained, but when  $\text{Zn}^{2+}$  ions bind to amylin peptides to form  $\text{Zn}^{2+}$ -amylin oligomers, the polymorphism is decreased, *i.e.*  $\text{Zn}^{2+}$  ions bind only to specific classes of amylin. At low concentrations of  $\text{Zn}^{2+}$  ions the polymorphism is smaller than at high concentrations. Second, the structural features of the self-assembled amylin oligomers are not affected by the presence of  $\text{Zn}^{2+}$  ions. This study proposes new molecular mechanisms of the self-assembly of  $\text{Zn}^{2+}$ -amylin oligomers.

Received 13th June 2016,  
Accepted 6th July 2016

DOI: 10.1039/c6cp04105a

www.rsc.org/pccp

## 1. Introduction

The family of amyloid peptides and amyloid proteins that are related to amyloidogenic diseases are self-assembled either from synthetic peptides or globular proteins.<sup>1–5</sup> Amyloid assembly is a multistep process, starting from an isolated monomer of amyloid, followed by aggregation into oligomers and fibrils,<sup>6</sup> and it has become the subject of intensive research in soft matter and materials science.<sup>7,8</sup> The family of amyloid peptides and amyloid proteins emerge as potential scaffolds and biomaterials for the growth of mammalian cells.<sup>9</sup> Spectroscopic and calorimetric approaches have been employed to characterize the stability of aggregated amyloids and elucidate the complex mechanism of fibril polymerization and depolymerization.<sup>10</sup>

Metal ions are used to modulate the *in vitro* formation of protein nano-objects for creating functional materials.<sup>7,8</sup> Metal ions also affect amyloid aggregation, promoting precipitation and fibrillogenesis, and alter the morphology of aggregates.<sup>11</sup> Transition metals such as  $\text{Cu}^{2+}$ ,  $\text{Fe}^{3+}$  and  $\text{Zn}^{2+}$  are particularly interesting as they are found at high concentrations in the core and periphery of senile amyloid plaque deposits.<sup>12</sup> It was shown that  $\text{Cu}^{2+}$ ,  $\text{Fe}^{3+}$  and  $\text{Zn}^{2+}$  promote the aggregation of  $\alpha$ -synuclein

in the brain of patients with Parkinson's disease (PD).<sup>13–15</sup> The role of metal ions in other amyloid peptides and proteins with regard to amyloid aggregation is well-documented.  $\text{Cu}^{2+}$  and  $\text{Zn}^{2+}$  ions that have been found in the brain of Creutzfeldt-Jacob patients showed induction of prion aggregates.<sup>16–19</sup> Extensive studies have shown that the contribution of  $\text{Cu}^{2+}$  and  $\text{Zn}^{2+}$  ions to the pathology of Alzheimer's disease (AD) is by promoting A $\beta$  aggregation.<sup>20–22</sup> Furthermore, the characterization of the structures of  $\text{Cu}^{2+}$ -A $\beta$  and  $\text{Zn}^{2+}$ -A $\beta$  oligomers and fibrils was extensively investigated both by experimental and computational studies.<sup>22–25</sup>

Amylin, which is also known as human islet amyloid polypeptide (hIAPP), is an endocrine hormone that consists of a 37-residue sequence and is a member of the family of amyloid peptides and proteins. *In vitro* studies have shown that  $\text{Cu}^{2+}$  ions inhibit the formation of amylin fibrils,<sup>26,27</sup> and prevent the formation of the  $\beta$ -sheet structures of amylin that are identified as oligomers and fibrils.<sup>28</sup> Yet, studying the role of  $\text{Zn}^{2+}$  in amylin aggregation is particularly of greater interest than the role of  $\text{Cu}^{2+}$  ions. While  $\text{Cu}^{2+}$  ions do not emerge from the pancreas together with amylin, it is known that amylin and  $\text{Zn}^{2+}$  ions are stored and packed inside the  $\beta$ -cell granules in the pancreatic islets<sup>29,30</sup> and enter the blood stream together.<sup>29</sup> In the pathological state of type 2 diabetes (T2D), amylin peptides aggregate to form various fibrillary structures.<sup>31,32</sup> Furthermore, it is well-known that during the aggregation of amylin, toxic species of amylin oligomers are involved with the progressive process of  $\beta$ -cell destruction in T2D.<sup>28,33–35</sup> It is also known that amylin and  $\text{Zn}^{2+}$  ions have a crucial role in glycemic regulation,

<sup>a</sup> Department of Chemistry, Ben-Gurion University of the Negev, P.O. Box 653, Be'er Sheva 84105, Israel. E-mail: ymiller@bgu.ac.il; Fax: +972-86428709; Tel: +972-86428705

<sup>b</sup> Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Be'er-Sheva 84105, Israel

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6cp04105a



but interruption in their delicate balance may cause the aggregation of amylin and thus the progression of T2D.<sup>33,34</sup> Therefore, amylin peptides can interact with  $\text{Zn}^{2+}$  ions to form similar amyloid plaque deposits as other amyloids. Yet, the mechanisms and chemistry through which  $\text{Zn}^{2+}$  ions interact with the toxic amylin oligomers are still elusive.

*In vitro* studies have shown that  $\text{Zn}^{2+}$  ions play a role in promoting amylin aggregation<sup>30,36,37</sup> and it was suggested that  $\text{Zn}^{2+}$  ions bind only to His18 in the amylin monomer.<sup>37,38</sup> Ramamoorthy and coworkers proposed that  $\text{Zn}^{2+}$  ions have a complex effect on amylin aggregation because the  $\text{Zn}^{2+}$  ions have different effects depending on the various stages of amylin aggregation. At an early stage of aggregation (40 min) and at high concentrations of  $\text{Zn}^{2+}$  ions (10 mM), the  $\text{Zn}^{2+}$  ions induce the formation of large sizes of  $\text{Zn}^{2+}$ -amylin aggregates compared with the absence of  $\text{Zn}^{2+}$  ions. However, at an early stage of aggregation (40 min) and at low concentrations of  $\text{Zn}^{2+}$  ions (100  $\mu\text{M}$ ), the  $\text{Zn}^{2+}$  ions promote the formation of even larger sizes of  $\text{Zn}^{2+}$ -amylin aggregates than those that are formed at high  $\text{Zn}^{2+}$  concentrations.<sup>39</sup> At the later stage of aggregation in which amylin fibrils are formed, the  $\text{Zn}^{2+}$  ions inhibit fibril formation at low concentrations, but the  $\text{Zn}^{2+}$  ions accelerate the formation of fibrils at higher concentrations.<sup>37,39,40</sup>

Despite the extensive work done previously, there are still questions that remain to be solved. How  $\text{Zn}^{2+}$  ions bind to amylin oligomers at the atomic resolution, *i.e.* what are the coordination binding sites? How  $\text{Zn}^{2+}$  ions affect the structure and stability of amylin oligomers? and what are the possible zinc:amylin ratios in amylin oligomers? This work is the first study that is aimed to address these important questions.

To address these issues, we applied our previous amylin oligomers,<sup>41</sup> which were derived from the structural ssNMR models<sup>31</sup> and from the crystal structural models.<sup>32</sup> We have shown that there are four different amylin oligomers that are derived from the experimental studies that vary by the orientation of the residues along the sequence of the  $\beta$ -arch structure of amylin oligomers. Herein, we present a first study that investigates the specific binding sites in the various amylin oligomers, considering His18 as a potential residue that binds  $\text{Zn}^{2+}$  ions, as previously proposed by ssNMR.<sup>39,40</sup> In order to provide insight into the effect of  $\text{Zn}^{2+}$  ions on the structure and the stability of amylin oligomers, we compare the structural characterization of  $\text{Zn}^{2+}$ -amylin oligomers *versus* our previous amylin oligomers (in the absence of  $\text{Zn}^{2+}$  ions). Finally, we examine various  $\text{Zn}^{2+}$ :amylin ratios, which have been proposed by experimental studies.<sup>39,40</sup> Our molecular dynamics (MD) simulations revealed that  $\text{Zn}^{2+}$  ions selectively bind to specific classes of amylin oligomers thus reducing the polymorphism, but within these classes of  $\text{Zn}^{2+}$ -amylin oligomers, polymorphic states were characterized due to the various concentrations of  $\text{Zn}^{2+}$  ions.

## 2. Experimental section

### Molecular dynamics (MD) simulations protocol

We constructed various models of  $\text{Zn}^{2+}$ -amylin octamers with different  $\text{Zn}^{2+}$ :amylin ratios by using Accelrys Discovery

Studio software.<sup>42</sup> Since the His18 residues in all constructed models bind  $\text{Zn}^{2+}$  ions, all His18 residues were deprotonated. MD simulations of the solvated models were performed in the *NPT* ensemble using the NAMD package<sup>43</sup> with the CHARMM27 force field.<sup>44,45</sup> The models were energy minimized and explicitly solvated in a TIP3P water box<sup>46,47</sup> with a minimum distance of 15 Å from each edge of the box. Each water molecule within 2.5 Å of the models was removed. Counter ions were added at random locations to neutralize the models' charge. The Langevin piston method<sup>43,48,49</sup> with a decay period of 100 fs and a damping time of 50 fs was used to maintain a constant pressure of 1 atm. A temperature of 330 K was controlled using a Langevin thermostat with a damping coefficient of 10  $\text{ps}^{-1}$ .<sup>43</sup> The short-range van der Waals interactions were calculated using the switching function, with a twin range cut-off of 10.0 and 12.0 Å. Long-range electrostatic interactions were calculated using the particle mesh Ewald method with a cutoff of 12.0 Å.<sup>48,50</sup> The equations of motion were integrated using the leapfrog integrator with a step of 1 fs. The solvated systems were energy minimized for 2000 conjugated gradient steps, where the hydrogen bonding distance between the  $\beta$ -sheets in each oligomer was fixed in the range 2.2–2.5 Å. The counter ions and water molecules were allowed to move. The hydrogen atoms were constrained to the equilibrium bond using the SHAKE algorithm.<sup>51</sup> The minimized solvated systems were energy minimized for 5000 additional conjugate gradient steps and 20 000 heating steps at 250 K, with all atoms being allowed to move. Then, the system was heated from 250 to 330 K for 300 ps and equilibrated at 330 K for 300 ps. All simulations were run for 50 ns at 330 K. These conditions were applied to all of the  $\text{Zn}^{2+}$ -amylin octamers. The temperature of 330 K (which is higher than room/body temperature) has been chosen in order to investigate the stability of the  $\text{Zn}^{2+}$ -amylin oligomers. Obviously,  $\text{Zn}^{2+}$ -amylin oligomers that are stable at this temperature will be stable also at lower temperatures. The timescale of 50 ns has been examined for all simulated  $\text{Zn}^{2+}$ -amylin octamers to ensure that this timescale is sufficient for these systems (see the Results and discussion section).

### Analysis details

We examined the structural stability of the studied models by following the changes in the number of hydrogen bonds between  $\beta$ -strands, with the hydrogen bond cut-off being set to 2.5 Å. We further computed the root-mean square deviations (RMSDs), root-mean square fluctuations (RMSFs) and monitored the change in the inter-sheet distance ( $\text{C}\alpha$  backbone-backbone distance) in the core domain of all of the simulated  $\text{Zn}^{2+}$ -amylin octamers. We estimated the core domain, as we previously estimated for amylin oligomers.<sup>41</sup> In all the simulated  $\text{Zn}^{2+}$ -amylin octamers that are based on model A2, the core domain was defined as the distance between residue 12 and residue 30. In all the simulated  $\text{Zn}^{2+}$ -amylin octamers that are based on model A3, the distance between residue 12 and residue 29 was defined as the core domain. Finally, we estimated the average number of water molecules around each side-chain  $\text{C}\beta$  carbon within 4 Å for each simulated  $\text{Zn}^{2+}$ -amylin octamer.



### Generalized born method with molecular volume (GBMV)

To obtain the relative conformational energies of the previous simulated amylin octamers<sup>41</sup> and the current simulated  $\text{Zn}^{2+}$ -amylin octamers, the trajectories of the last 5 ns of each simulated  $\text{Zn}^{2+}$ -amylin octamer were first extracted from the explicit MD simulation excluding the water molecules. The solvation energies of all systems were calculated using the GBMV.<sup>52,53</sup> In the GBMV calculations, the dielectric constant of water was set to 80. The hydrophobic solvent-accessible surface area (SASA) term factor was set to  $0.00592 \text{ kcal mol}^{-1} \text{ \AA}^{-2}$ . Each conformer was minimized using 1000 cycles, and the conformational energy was evaluated by grid-based GBMV.

A total of 1500 conformations (500 conformations for each of the 3 previous conformers<sup>41</sup>) were used to construct the energy landscape of the simulated amylin octamer that are based on model A2 (models M2, M2D and M5) and to evaluate the conformer probabilities by using Monte Carlo (MC) simulations. Similarly, a total of 1500 conformations were used: 500 conformations for each of the 2 examined conformers of the simulated  $\text{Zn}^{2+}$ -amylin octamers that are based on model A2 with the  $\text{Zn}^{2+}$ : amylin ratio of 1:2 (models R1 and R2) and one examined conformer simulated  $\text{Zn}^{2+}$ -amylin octamer that is based on model A3 with the  $\text{Zn}^{2+}$ : amylin ratio of 1:2 (model S1). Finally, we used 1000 conformations, 500 conformations for each of the 2 examined conformers: one for the simulated  $\text{Zn}^{2+}$ -amylin octamer that is based on model A2 with the  $\text{Zn}^{2+}$ : amylin ratio of 1:4 (model R3) and the second for the simulated  $\text{Zn}^{2+}$ -amylin octamer that is based on model A3 with the  $\text{Zn}^{2+}$ : amylin ratio of 1:4 (model S3).

In the first step, one conformation of conformer *i* and one conformation of conformer *j* were randomly selected. Then, the Boltzmann factor was computed as  $e^{-(E_j - E_i)/KT}$ , where  $E_i$  and  $E_j$  are the conformational energies evaluated using the GBMV calculations for conformations *i* and *j*, respectively,  $K$  is the Boltzmann constant and  $T$  is the absolute temperature (298 K used here). If the value of the Boltzmann factor was larger than the random number, then the move from conformation *i* to conformation *j* was allowed. After 1 million steps, the conformations 'visited' for each conformer were counted.

## 3. Results and discussion

### $\text{Zn}^{2+}$ ions selectively bind to specific classes of amylin oligomers

It has been shown by Ramamoorthy's group that  $\text{Zn}^{2+}$  ions in amylin solution lead to the formation of oligomers and fibrils.<sup>37,39</sup> Therefore, the  $\text{Zn}^{2+}$  ions induce the formation of the cross- $\beta$  structure of amylin and thus our initial constructed models here are based on the amylin oligomers and fibril-like structures with their self-assembled cross- $\beta$  structure. Previously,<sup>41</sup> we generated eight various molecular structural amylin cross- $\beta$  octamers of single- and double-layer conformations applying models A1–A4 as 'building blocks' from Tycko's<sup>31</sup> and Eisenberg's<sup>32</sup> coordinates (Fig. 1). These four models share the same sequence of 37 residues of amylin, but they differ in the orientations of the residues both along the backbone of the two  $\beta$ -strands and the




Fig. 1 Representation of the molecular models of the fibril-like structures of amylin that differ in the orientations of the residues along the  $\beta$ -arch and the turn domain. The models were extracted from experimental studies<sup>31,32</sup> and from our previous work.<sup>41</sup> Residue colors: Arg11, red; His18, blue; Asn19, purple; and Asn31, green.

U-turn of the  $\beta$ -arch structure of amylin. A particular difference that is related to this study is the location of His18 in the U-turn domain of amylin. In models A1 and A4, His18 is located inside the core domain, while in models A2 and A3 His18 is located outside the core domain (Fig. 1).

We first examined the binding site of  $\text{Zn}^{2+}$  ions in amylin oligomers that are based on these four models A1–A4 for single- and double-layer conformations. The  $\text{Zn}^{2+}$  ions were interacted with His18, since it was suggested that  $\text{Zn}^{2+}$  ions bind to His18 in the amylin monomer.<sup>37,38</sup> We constructed various conformations with the  $\text{Zn}^{2+}$ : amylin ratio of 1:2 models Q1, Q2, T1 and T2 (Fig. 2) and R1, R2, S1 and S2 (Fig. 3). Table 1 summarizes these various conformations of  $\text{Zn}^{2+}$ -amylin oligomers. The single- and the double-layer conformations that were constructed from models A1 (models Q1 and Q2) and A4 (models T1 and T2), in which His18 is located in the core domain, illustrated unstable  $\text{Zn}^{2+}$ -amylin oligomers. During minimization, the  $\text{Zn}^{2+}$  ions escaped upon interaction with His18. We suggest that the steric effects inside the core domain in the  $\beta$ -arch domain of the amylin oligomers do not allow  $\text{Zn}^{2+}$  ions to interact with His18 residues (Fig. S1, ESI†). We therefore propose that  $\text{Zn}^{2+}$  ions do not bind to amylin oligomers that are based on models A1 and A4 and thus decrease the polymorphism, which is strongly reflected in the aggregation of amylin with the absence of  $\text{Zn}^{2+}$  ions, as we previously demonstrated for amylin oligomers.<sup>41</sup>

In models A2 and A3 His18 is located outside the core domain of the  $\beta$ -arch. The single- and the double-layer conformations of models R1 and R2, which are based on model A2, and the single-layer conformation model S1, which is based on model A3, demonstrated that during minimization and MD simulations the  $\text{Zn}^{2+}$  ions were not escaped from the binding site. Surprisingly, in the double-layer conformation model S2, which is based on model A3, the  $\text{Zn}^{2+}$  ions escaped from the binding site after 5 ns of simulations (Fig. S2, ESI†). Finally, for the  $\text{Zn}^{2+}$ : amylin ratio of 1:4, only single-layer conformation model R3 is based on model A2 and single-layer conformation model S3 is allowed to bind  $\text{Zn}^{2+}$  ions within this ratio. Table 1 summarizes these two conformations of  $\text{Zn}^{2+}$ -amylin oligomers with the ratio of 1:4. We therefore focused our simulations and






Fig. 2 Single- and double-layer constructed models of the  $\text{Zn}^{2+}$ -amylin oligomer in which the amylin peptides are composed of A1 (models Q1 and Q2) and A4 (models T1 and T2). The  $\text{Zn}^{2+}$ : amylin ratio is 1 : 2, i.e. each  $\text{Zn}^{2+}$  ion binds two His18 of two peptides in the core domain. Residue colors: Arg11, red; His18, blue; Asn19, purple; and Asn31, green.




Fig. 3 Single- and double-layer constructed models of the  $\text{Zn}^{2+}$ -amylin oligomer in which the amylin peptides are composed of A2 (models R1 and R2) and A3 (models S1 and S2). The  $\text{Zn}^{2+}$ : amylin ratio is 1 : 2, i.e. each  $\text{Zn}^{2+}$  ion binds two His18 of two peptides. Residue colors: Arg11, red; His18, blue; Asn19, purple; and Asn31, green.

analysis only on models R1, R2 and S1 for the  $\text{Zn}^{2+}$ : amylin ratio of 1 : 2 and R3 and S3 for the ratio of 1 : 4.

### Examining the variety of $\text{Zn}^{2+}$ coordination modes in amylin oligomers

In numerous biological systems  $\text{Zn}^{2+}$  ions bind to ligands, such as amino acids and water molecules. Since it is known that

Table 1 A detailed description of the various constructed models of  $\text{Zn}^{2+}$ -amylin oligomers

Model	Constructed from A type model	Conformation	$\text{Zn}^{2+}$ : amylin ratio
Q1	A1	Single layer	1 : 2
Q2	A1	Double layer	1 : 2
T1	A4	Single layer	1 : 2
T2	A4	Double layer	1 : 2
R1	A2	Single layer	1 : 2
R2	A2	Double layer	1 : 2
S1	A3	Single layer	1 : 2
S2	A3	Double layer	1 : 2
R3	A2	Single layer	1 : 4
S3	A3	Single layer	1 : 4

$\text{Zn}^{2+}$  ions bind His18 in the amylin monomer,<sup>37</sup> it is great of interest to investigate the  $\text{Zn}^{2+}$ : amylin ratio in  $\text{Zn}^{2+}$ -amylin oligomers. To examine the possible  $\text{Zn}^{2+}$ : amylin ratio in  $\text{Zn}^{2+}$ -amylin oligomers, we constructed various  $\text{Zn}^{2+}$ : amylin ratios of octamers that are based on models A2 and A3. There is a diversity of coordination modes of  $\text{Zn}^{2+}$  ions in proteins. It has been suggested that  $\text{Zn}^{2+}$  ions can bind to 4–6 amino acids or/and water molecules in proteins.<sup>54</sup> Yet, it has been suggested that  $\text{Zn}^{2+}$  ions prefer the tetrahedral coordination mode, i.e. 4 amino acids/water molecules in proteins.<sup>54–56</sup> Previously Ramamoorthy's group suggested that  $\text{Zn}^{2+}$  ions bind to 3, 4 and 6 helical amylin monomeric structure in His18.<sup>39,40</sup> Yet, Ramammorthy's group also suggested that  $\text{Zn}^{2+}$  ions induce the formation of amylin fibrils, i.e. cross- $\beta$  structures of amylin. Therefore, the coordination mode of  $\text{Zn}^{2+}$  ions in the self-assembled cross- $\beta$  structure of amylin oligomers is still unknown. To address this issue, we examined various  $\text{Zn}^{2+}$ : amylin ratios of 1 : 1 (Fig. S3, ESI<sup>†</sup>), 1 : 2 (models R1, R2 and S1) and 1 : 4 (models R3 and S3). The ratio of 1 : 3 has not been examined here and ongoing work is performed in our group to examine this ratio. Finally, the ratio of 1 : 6 may be applicable to be examined for the six helical monomeric structures of amylin,<sup>39,40</sup> but this ratio cannot be applicable in the cross- $\beta$  structure of amylin oligomers that are studied here.

We examined the  $\text{Zn}^{2+}$ : amylin ratio of 1 : 1 for both single and double-layer conformations that are based on models A2 and A3. Not surprisingly, the  $\text{Zn}^{2+}$  ions were escaped from the binding site, probably due to the electrostatic repulsions between the  $\text{Zn}^{2+}$  ions (Fig. S3, ESI<sup>†</sup>). Furthermore, it is more likely that the  $\text{Zn}^{2+}$ : protein ratio or the  $\text{Zn}^{2+}$ : amylin ratio of 1 : 1 is not possible when the  $\text{Zn}^{2+}$  ion binds to only one residue, such as His18 in amylin, and our simulations provided support to this hypothesis.

As seen in Fig. 3, we also examined the  $\text{Zn}^{2+}$ : amylin ratio of 1 : 2 both for single- and double layer conformations that are based on models A2 (models R1 and R2) and A3 (model S1). Our simulations suggest that each  $\text{Zn}^{2+}$  ion binds to two N $\epsilon$  atoms (each of two His18 residues of two amylin monomers) in these models, and four O atoms of water molecules complete the coordination mode to six coordination by forming an octahedral molecular geometry (Fig. S4 and Table S1, ESI<sup>†</sup>). Interestingly, the ratio of  $\text{Zn}^{2+}$ : A $\beta$  of 1 : 2 has also been illustrated by








Fig. 4 Constructed models of the  $\text{Zn}^{2+}$ -amylin oligomer in which the amylin peptides are composed of A2 (model R3) and A3 (model S3). The  $\text{Zn}^{2+}$ : amylin ratio is 1: 4, i.e. each  $\text{Zn}^{2+}$  ion binds four His18 of four peptides. Residue colors: Arg11, red; His18, blue; Asn19, purple; and Asn31, green.

Miller *et al.* for  $\text{Zn}^{2+}$ -A $\beta$  oligomers; however, the completion of coordination with water molecules has not been studied for these oligomers.<sup>25</sup> As noted in the previous section, surprisingly, in the double-layer conformation model S2, which is based on model A3, the  $\text{Zn}^{2+}$  ions escaped from the binding site after 5 ns of the simulations (Fig. S2, ESI<sup>†</sup>).

Finally, we examined the  $\text{Zn}^{2+}$ : amylin ratio of 1: 4 for models that are based on model A2 (model R3) and model A4 (model S3). In each one of models R3 and S3, two single-layer conformations were joined together by  $\text{Zn}^{2+}$  ions (Fig. 4). These two models, R3 and S3, exhibited stable  $\text{Zn}^{2+}$ -amylin oligomers. Each  $\text{Zn}^{2+}$  ion in these two models binds to N $\epsilon$  atoms (each of four His18 residues of four amylin monomers) and two water molecules (Fig. S5 and Table S2, ESI<sup>†</sup>). The  $\text{Zn}^{2+}$ : A $\beta$  ratio of 1: 4 has also been shown by Miller *et al.* for  $\text{Zn}^{2+}$ -A $\beta$  oligomers, but the completion of the coordination with water molecules has not been shown.<sup>25</sup> It should be noted that the ratio of 1: 4 cannot allow the formation of double-layer conformations of  $\text{Zn}^{2+}$ -amylin oligomers in the well-organized cross- $\beta$  structure.

### Polymorphic states of $\text{Zn}^{2+}$ -amylin oligomers depend on the concentration of $\text{Zn}^{2+}$ ions

We have previously shown that amylin oligomers exhibit polymorphic states, i.e. there are several conformations of amylin oligomers with similar energies and similar populations.<sup>41</sup> It was previously suggested that  $\text{Zn}^{2+}$  ions increase the polymorphism in A $\beta$  oligomers.<sup>23,57</sup> Herein, we showed that because  $\text{Zn}^{2+}$  ions cannot bind to all polymorphic amylin oligomers, the  $\text{Zn}^{2+}$  ions decrease polymorphism in amylin oligomers. Yet, within the structures of  $\text{Zn}^{2+}$ -amylin oligomers, it is of great interest to examine whether binding  $\text{Zn}^{2+}$  ions to amylin oligomers may also lead to polymorphism. To investigate this issue, we estimated the conformational energies of  $\text{Zn}^{2+}$ -amylin oligomer models with the  $\text{Zn}^{2+}$ : amylin ratio of 1: 2, which are based on model A2: models R1, R2 and the model that is based on A3: model S1. We further estimated the conformational energies of  $\text{Zn}^{2+}$ -amylin oligomer models with the  $\text{Zn}^{2+}$ : amylin ratio of 1: 4 for the model that is based on A2 (model R3) and models that are based on A3 (model S3). The values of the averaged

conformational energies are listed in Table S3 (ESI<sup>†</sup>). Finally, we estimated the relative conformational energies values of the equivalent amylin oligomers: models M2, M2d and M5 from our previous study.<sup>41</sup> The values of the averaged conformational energies are also listed in Table S3 (ESI<sup>†</sup>).

The averaged conformational energies and the distribution of the last 500 conformations for these models are in seen in Fig. 5. One can see that with the absence of  $\text{Zn}^{2+}$  ions the energy difference between amylin oligomers that are based on model A2 (model M2 and M2d) and the amylin oligomer that is based on model A3 (model M5) is in the range of 200–320 kcal mol<sup>−1</sup>. However, these are not the only models of amylin oligomers, as we previously shown, amylin oligomers are polymorphic and there are at least 12 different amylin oligomers.<sup>41</sup> When adding  $\text{Zn}^{2+}$  ions with the  $\text{Zn}^{2+}$ : amylin ratio of 1: 4, the energy difference between the models that are based on model A2 (model R3) and the model that is based on model A3 (model S3) is  $\sim 250$  kcal mol<sup>−1</sup>. Therefore, we suggest that adding relatively low concentrations of  $\text{Zn}^{2+}$  ions decrease polymorphism and yield a relatively high preference of one model over the other model. In this case, model R3 is highly preferred over model S3. However, at higher concentrations, i.e. in the  $\text{Zn}^{2+}$ : amylin ratio of 1: 2, the energy difference between the models that are based




Fig. 5 Distributions of the conformational energy values (obtained from the GBMV calculations<sup>52,53</sup>) of the simulated models of amylin oligomers M2, M5 and M5d (obtained from our previous study), simulated models of  $\text{Zn}^{2+}$ -amylin oligomers with the  $\text{Zn}^{2+}$ : amylin ratio of 1: 2 – models R1, R2, and S1 and simulated models of  $\text{Zn}^{2+}$ -amylin oligomers with the  $\text{Zn}^{2+}$ : amylin ratio of 1: 4 – models R3 and S3.



on model A2 (models R1 and R2) and the model that is based on A3 (model S1) is  $\sim 100$  kcal mol $^{-1}$ . Thus, at high concentrations of Zn $^{2+}$  ions, the polymorphic states are increased compared with low concentration of Zn $^{2+}$  ions, and models that are based on both A2 and A3 are preferred. Obviously, the polymorphism in such a case is relatively low compared with the case with the absence of Zn $^{2+}$  ions.

Previously, it was suggested by Miller *et al.*<sup>58</sup> that A $\beta$  oligomers present polymorphic states and that metal ions increase the polymorphism, as previously shown for Zn $^{2+}$ -A $\beta_{1-42}$  oligomers.<sup>25</sup> Interestingly, we found that in amylin the Zn $^{2+}$  ions may decrease or increase the polymorphism within the classes of amylin oligomers due to the concentrations of Zn $^{2+}$ , *i.e.*, due to the Zn $^{2+}$ :amylin ratio.

### Zn $^{2+}$ ions do not change the structural features of amylin oligomers

A previous study by Ramamoorthy's group has shown that both in the absence and in the presence of Zn $^{2+}$  ions, amylin peptides are self-assembled into fibrillar structures, *i.e.* forming cross- $\beta$  structures, and that the structural features are similar.<sup>39</sup> To investigate the structural features of our simulated Zn $^{2+}$ -amylin oligomer models, we first examined whether the fibril-like structures are well-packed (Fig. S6, ESI $^{\dagger}$ ). We further estimated the percentage of hydrogen bonds along the cross- $\beta$  structure that are retained throughout the MD simulations (Fig. S7, ESI $^{\dagger}$ ). Finally, we computed the root-mean square deviations (RMSDs) (Fig. S8, ESI $^{\dagger}$ ). These analyses show that all simulated models are well-packed with cross- $\beta$  fibrillar structures, as suggested by the experimental observation.<sup>39</sup> Furthermore, the RMSD analyses show that all simulated models were structurally converged in the last 10 ns of the simulations.

To focus in more detail on the structural stability, we performed analysis of the secondary structure of the simulated amylin oligomers. According to dihedral angles  $\psi$  and  $\phi$  analysis, the secondary structure of the Zn $^{2+}$ -amylin oligomers is similar

to our previous equivalent amylin oligomers (Fig. 6). As seen in the secondary structure of the studied models, the two  $\beta$ -strand domains (residues 8–17 and residues 26–37) retained the stability, similarly to the equivalent amylin oligomer models that we previously studied.<sup>41</sup> Therefore, we propose that the Zn $^{2+}$  ions do not change the formation of stable cross- $\beta$  structures of amylin, as previously suggested by experimental observations.<sup>39</sup>

### Zn $^{2+}$ ions affect the turn domains of specific classes of amylin oligomers

As noted above, the Zn $^{2+}$  ions that bind to amylin oligomers in models that are based on models A2 and A3 in this study for both the ratios of Zn $^{2+}$ :amylin of 1:2 and 1:4 have no significant effect on the secondary structure of the turn domain (Fig. 6). The secondary structure of the Zn $^{2+}$ -amylin oligomers demonstrates a similar secondary structure to the equivalent amylin oligomers.

Since the Zn $^{2+}$  ions bind to His18 that is located in the turn domain of the  $\beta$ -arch of the self-assembled amylin, it is important to examine whether the Zn $^{2+}$  ions affect the morphologies of this domain. To examine the fluctuations of the simulated amylin oligomers (M2, M2d and M5) and the equivalent simulated Zn $^{2+}$ -amylin oligomers, we computed the root-mean square fluctuations (RMSFs) for each residue of the amylin oligomers (Fig. 7). We previously have shown that the turn domain of all amylin oligomer models fluctuates relatively more than the two  $\beta$ -strands domains.<sup>41</sup> Specifically, the turn domain of model M2 (which are based on model A2) illustrated relatively less fluctuations than that of model M5 (which is based on model A3) (Fig. S7, ESI $^{\dagger}$ ).




Fig. 6 The secondary structure along the sequence of amylin of the simulated models of the simulated models amylin oligomers M2, M5 and M5d (obtained from our previous study), simulated models of Zn $^{2+}$ -amylin oligomers with the Zn $^{2+}$ :amylin ratio of 1:2 – models R1, R2, and S1 and simulated models of Zn $^{2+}$ -amylin oligomers with the Zn $^{2+}$ :amylin ratio of 1:4 – models R3 and S3. The arrows illustrate the  $\beta$ -strand structure.




Fig. 7 RMSFs of the simulated models of amylin oligomers M2 and M5 (obtained from our previous study), simulated models of Zn $^{2+}$ -amylin oligomers with the Zn $^{2+}$ :amylin ratio of 1:2 – models R1 and S1 and simulated models of Zn $^{2+}$ -amylin oligomers with the Zn $^{2+}$ :amylin ratio of 1:4 – models R3 and S3.



Herein, one can see a similar scenario for both ratios of  $\text{Zn}^{2+}$ :amylin of 1:2 and 1:4 (Fig. 7). In models that are based on model A2 (models R1, R2 and R3), the turn domain fluctuates less compared with the turn domain in models that are based on model A3 (models S1 and S3).

Interestingly, these fluctuations more likely affect the inter-sheet distance ( $\text{C}\alpha$  backbone–backbone distance) in the core domain of amylin oligomers. The inter-sheet distances of models R1 and R3 demonstrate relatively smaller values than those of models S1 and S3 (Fig. S6, ESI†). Indeed, one can see from Fig. 7 that the fluctuations of residues in the N-terminal domain of model S1 are relatively large compared to those of model R1. Therefore, it indicates that the cross- $\beta$  structures of models R1 and R3 are well packed compared to those of models S1 and S3.

Finally, the turn domains in models that are based on model A2 are more solvated than models that are based on model A3 for both ratios of  $\text{Zn}^{2+}$ :amylin of 1:2 and 1:4 (Fig. S9, ESI†). One can see that the turn domain of model S1 is more solvated than that of model R1 (and R2) and the turn domain of model S3 is more solvated than that of model R3. Interestingly, the solvation of the turn domain is in accordance with the fluctuation of the turn domain (Fig. 7). When the turn domain fluctuates more, it is more exposed to solvent and therefore it is more solvated.

## 4. Conclusions

Amylin aggregation is associated with  $\beta$ -cell death in T2D. The role of  $\text{Zn}^{2+}$  in T2D is controversial. It is known that patients with T2D have zinc deficiency in  $\beta$ -cells.<sup>59</sup> One of the fundamental questions is what is the effect of zinc deficiency in  $\beta$ -cell granules on the development of T2D, such as on the aggregation of amylin. Previously, it was suggested that amylin and  $\text{Zn}^{2+}$  ions have a crucial role in glycemic regulation, but interruption in their delicate balance may cause aggregation of amylin and thus the progression of T2D.<sup>33,34</sup> It has been suggested that  $\text{Zn}^{2+}$  ions interact with amylin peptides and lead to the self-assembly of amylin peptides into fibrillar structures, *via* the oligomeric toxic species.<sup>39</sup> In this study we investigated the interactions of the  $\text{Zn}^{2+}$  ions within the amylin peptides at the atomic resolution in the toxic oligomeric states of amylin. Specifically, we investigated the effect of these interactions on the self-assembly of amylin. Our results led to two main conclusions. First, while polymorphic states were obtained in the absence of  $\text{Zn}^{2+}$  ions, *i.e.* various classes of amylin oligomers were present,<sup>41</sup> in the absence of  $\text{Zn}^{2+}$  ions only specific classes of amylin oligomers were obtained. We therefore suggest that  $\text{Zn}^{2+}$  ions decrease amylin polymorphism. Yet, the level of polymorphic states depends on the concentration of the  $\text{Zn}^{2+}$  ions. Fig. 8 illustrates the various mechanisms proposed for the formation of amylin oligomers at different concentrations of  $\text{Zn}^{2+}$  ions. At high concentrations of  $\text{Zn}^{2+}$  ions, various polymorphic states of  $\text{Zn}^{2+}$ –amylin oligomers are obtained, while at low concentrations of  $\text{Zn}^{2+}$  ions there is high preference for one  $\text{Zn}^{2+}$ –amylin oligomer. Second,  $\text{Zn}^{2+}$  ions do not affect the structural features of the self-assembly of amylin,




Fig. 8 Proposed molecular mechanism pathways of the formation of conformational  $\text{Zn}^{2+}$ –amylin oligomers with two classes (models A2 and A3) and with one class (model A2) of amylin oligomers at high concentrations of zinc ( $\text{Zn}^{2+}$ :amylin ratio of 1:2) and at low concentration of zinc ( $\text{Zn}^{2+}$ :amylin ratio of 1:4), respectively.

as previously shown by experimental measurements.<sup>39</sup> Yet, in several classes of amylin oligomers there are slight fluctuations in the turn domain of amylin, due to the interactions with the  $\text{Zn}^{2+}$  ions. It was found that the turn domain in the amylin peptide is crucial for seeding and for self-assembly of amylin into oligomers.<sup>60–64</sup> It was also proposed that at an early stage of amylin oligomerization in solution, amylin forms interactions between His18 and Tyr37, *i.e.* interactions between the turn domain (in which His18 is located and can bind  $\text{Zn}^{2+}$  ions) and the C-terminal of amylin (residue Tyr37).<sup>38</sup> We therefore suggest that interactions of the  $\text{Zn}^{2+}$  ions can affect the initiation of the process of amylin aggregation. Herein, we have shown that stable  $\text{Zn}^{2+}$ –amylin oligomers were less solvated, and thus more prone to aggregate. Yet, future experimental work is needed to approve this interesting finding from our simulations.

## Acknowledgements

This research was supported by the Israel Science Foundation (grant No. 532/15) and partly by the FP7-PEOPLE-2011-CIG, research grant no. 303741. All simulations were performed using the high-performance computational facilities of the Miller Lab in BGU HPC computational center. The support of the BGU HPC computational center staff is greatly appreciated.

## References

- M. N. Bongiovanni, D. B. Scanlon and S. L. Gras, Functional fibrils derived from the peptide TTR1-cycloRGDfK that target cell adhesion and spreading, *Biomaterials*, 2011, **32**, 6099–6110.
- G. A. Silva, C. Czeisler, K. L. Niece, E. Beniash, D. A. Harrington, J. A. Kessler and S. I. Stupp, Selective differentiation of neural progenitor cells by high-epitope density nanofibers, *Science*, 2004, **303**, 1352–1355.





- 3 C. Li, J. Adamcik and R. Mezzenga, Biodegradable nanocomposites of amyloid fibrils and graphene with shape-memory and enzyme-sensing properties, *Nat. Nanotechnol.*, 2012, **7**, 421–427.
- 4 N. P. Reynolds, M. Charnley, R. Mezzenga and P. G. Hartley, Engineered lysozyme amyloid fibril networks support cellular growth and spreading, *Biomacromolecules*, 2014, **15**, 599–608.
- 5 N. P. Reynolds, K. E. Styan, C. D. Easton, Y. Li, L. Waddington, C. Lara, J. S. Forsythe, R. Mezzenga, P. G. Hartley and B. W. Muir, Nanotopographic surfaces with defined surface chemistries from amyloid fibril networks can control cell attachment, *Biomacromolecules*, 2013, **14**, 2305–2316.
- 6 S. I. Cohen, S. Linse, L. M. Luheshi, E. Hellstrand, D. A. White, L. Rajah, D. E. Otzen, M. Vendruscolo, C. M. Dobson and T. P. Knowles, Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 9758–9763.
- 7 S. Bolisetty, J. J. Vallooran, J. Adamcik and R. Mezzenga, Magnetic-responsive hybrids of Fe<sub>3</sub>O<sub>4</sub> nanoparticles with beta-lactoglobulin amyloid fibrils and nanoclusters, *ACS Nano*, 2013, **7**, 6146–6155.
- 8 T. P. Knowles and M. J. Buehler, Nanomechanics of functional and pathological amyloid materials, *Nat. Nanotechnol.*, 2011, **6**, 469–479.
- 9 C. Zhong, T. Gurry, A. A. Cheng, J. Downey, Z. Deng, C. M. Stultz and T. K. Lu, Strong underwater adhesives made by self-assembling multi-protein nanofibres, *Nat. Nanotechnol.*, 2014, **9**, 858–866.
- 10 T. Ikenoue, Y. H. Lee, J. Kardos, H. Yagi, T. Ikegami, H. Naiki and Y. Goto, Heat of supersaturation-limited amyloid burst directly monitored by isothermal titration calorimetry, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 6654–6659.
- 11 S. S. Leal, H. M. Botelho and C. M. Gomes, Metal ions as modulators of protein conformation and misfolding in neurodegeneration, *Coord. Chem. Rev.*, 2012, **256**, 2253–2270.
- 12 A. I. Bush, The metallobiology of Alzheimer's disease, *Trends Neurosci.*, 2003, **26**, 207–214.
- 13 A. Prakash, K. Bharti and A. B. Majeed, Zinc: indications in brain disorders, *Fundam. Clin. Pharmacol.*, 2015, **29**, 131–149.
- 14 C. G. Dudzik, E. D. Walter and G. L. Millhauser, Coordination features and affinity of the Cu(2)+ site in the alpha-synuclein protein of Parkinson's disease, *Biochemistry*, 2011, **50**, 1771–1777.
- 15 M. Bisaglia, I. Tessari, S. Mammi and L. Bubacco, Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease, *NeuroMol. Med.*, 2009, **11**, 239–251.
- 16 F. Stellato, A. Spevacek, O. Proux, V. Minicozzi, G. Millhauser and S. Morante, Zinc modulates copper coordination mode in prion protein octa-repeat subdomains, *Eur. Biophys. J.*, 2011, **40**, 1259–1270.
- 17 A. A. Valiente-Gabioud, V. Torres-Monserrat, L. Molina-Rubino, A. Binolfi, C. Griesinger and C. O. Fernandez, Structural basis behind the interaction of Zn(2)(+) with the protein alpha-synuclein and the A-beta peptide: a comparative analysis, *J. Inorg. Biochem.*, 2012, **117**, 334–341.
- 18 E. Gaggelli, F. Bernardi, E. Molteni, R. Pogni, D. Valensin, G. Valensin, M. Remelli, M. Luczkowski and H. Kozlowski, Interaction of the human prion PrP (106–126) sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies, *J. Am. Chem. Soc.*, 2005, **127**, 996–1006.
- 19 E. D. Walter, D. J. Stevens, M. P. Visconte and G. L. Millhauser, The prion protein is a combined zinc and copper binding protein: Zn<sup>2+</sup> alters the distribution of Cu<sup>2+</sup> coordination modes, *J. Am. Chem. Soc.*, 2007, **129**, 15440–15441.
- 20 D. R. Brown and H. Kozlowski, Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases, *Dalton Trans.*, 2004, 1907–1917.
- 21 J. W. Karr and V. A. Szalai, Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide, *Biochemistry*, 2008, **47**, 5006–5016.
- 22 S. Parthasarathy, F. Long, Y. Miller, Y. Xiao, D. McElheny, K. Thurber, B. Ma, R. Nussinov and Y. Ishii, Molecular-level examination of Cu2 binding structure for amyloid fibrils of 40-residue Alzheimer's  $\beta$  by solid-state NMR spectroscopy, *J. Am. Chem. Soc.*, 2011, **133**, 3390–3400.
- 23 S. C. Drew, C. L. Masters and K. J. Barnham, Alanine-2 carbonyl is an oxygen ligand in Cu2 coordination of Alzheimer's disease amyloid- $\beta$  peptide-relevance to N-terminally truncated forms, *J. Am. Chem. Soc.*, 2009, **131**, 8760–8761.
- 24 C. Hureau and P. Faller, A $\beta$ -mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease, *Biochimie*, 2009, **91**, 1212–1217.
- 25 Y. Miller, B. Ma and R. Nussinov, Zinc ions promote Alzheimer A-beta aggregation via population shift of polymorphic states, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 9490–9495.
- 26 D. Drago, S. Bolognin and P. Zatta, Role of metal ions in the A $\beta$  oligomerization in Alzheimer's disease and in other neurological disorders, *Curr. Alzheimer Res.*, 2008, **5**, 500–507.
- 27 B. Ward, K. Walker and C. Exley, Copper(II) inhibits the formation of amylin amyloid *in vitro*, *J. Inorg. Biochem.*, 2008, **102**, 371–375.
- 28 K. Jeong, W. Y. Chung, Y. S. Kye and D. Kim, Cu(II) cyclen cleavage agent for human islet amyloid peptide, *Bioorg. Med. Chem.*, 2010, **18**, 2598–2601.
- 29 D. Li, S. Chen, E. A. Bellomo, A. I. Tarasov, C. Kaut, G. A. Rutter and W. H. Li, Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR), *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 21063–21068.
- 30 P. Westermark, Z. C. Li, G. T. Westermark, A. Leckstrom and D. F. Steiner, Effects of beta cell granule components on human islet amyloid polypeptide fibril formation, *FEBS Lett.*, 1996, **379**, 203–206.
- 31 S. Luca, W.-M. Yau, R. Leapman and R. Tycko, Peptide conformation and supramolecular organization in amylin





- fibrils: constraints from solid-state NMR, *Biochemistry*, 2007, **46**, 13505–13522.
- 32 J. J. W. Wiltzius, S. A. Sievers, M. R. Sawaya, D. Cascio, D. Popov, C. Riek and D. Eisenberg, Atomic structure of the cross- $\beta$  spine of islet amyloid polypeptide (amylin), *Protein Sci.*, 2008, **17**, 1467–1474.
  - 33 J. Janson, R. H. Ashley, D. Harrison, S. McIntyre and P. C. Butler, The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles, *Diabetes*, 1999, **48**, 491–498.
  - 34 R. A. Ritzel, J. J. Meier, C. Y. Lin, J. D. Veldhuis and P. C. Butler, Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets, *Diabetes*, 2007, **56**, 65–71.
  - 35 S. Sakagashira, H. J. Hiddinga, K. Tateishi, T. Sanke, T. Hanabusa, K. Nanjo and N. L. Eberhardt, S20G mutant amylin exhibits increased *in vitro* amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin, *Am. J. Pathol.*, 2000, **157**, 2101–2109.
  - 36 F. Bellia and G. Grasso, The role of copper(II) and zinc(II) in the degradation of human and murine IAPP by insulin-degrading enzyme, *J. Mass Spectrom.*, 2014, **49**, 274–279.
  - 37 J. R. Brender, K. Hartman, R. P. Nanga, N. Popovych, R. de la Salud Bea, S. Vivekanandan, E. N. Marsh and A. Ramamoorthy, Role of zinc in human islet amyloid polypeptide aggregation, *J. Am. Chem. Soc.*, 2010, **132**, 8973–8983.
  - 38 L. Wei, P. Jiang, W. Xu, H. Li, H. Zhang, L. Yan, M. B. Chan-Park, X. W. Liu, K. Tang, Y. Mu and K. Pervushin, The molecular basis of distinct aggregation pathways of islet amyloid polypeptide, *J. Biol. Chem.*, 2011, **286**, 6291–6300.
  - 39 J. R. Brender, J. Krishnamoorthy, G. M. Messina, A. Deb, S. Vivekanandan, C. La Rosa, J. E. Penner-Hahn and A. Ramamoorthy, Zinc stabilization of prefibrillar oligomers of human islet amyloid polypeptide, *Chem. Commun.*, 2013, **49**, 3339–3341.
  - 40 S. Salamekh, J. R. Brender, S. J. Hyung, R. P. Nanga, S. Vivekanandan, B. T. Ruotolo and A. Ramamoorthy, A two-site mechanism for the inhibition of IAPP amyloidogenesis by zinc, *J. Mol. Biol.*, 2011, **410**, 294–306.
  - 41 V. Wineman-Fisher, Y. Atsmon-Raz and Y. Miller, Orientations of residues along the beta-arch of self-assembled amylin fibril-like structures lead to polymorphism, *Biomacromolecules*, 2015, **16**, 156–165.
  - 42 <http://accelrys.com/products/discovery-studio/>.
  - 43 L. Kalé, R. Skeel, M. Bhandarkar, R. Brunner, A. Gursoy, N. Krawetz, J. Phillips, A. Shinozaki, K. Varadarajan and K. Schulten, NAMD2: greater scalability for parallel molecular dynamics, *J. Comput. Phys.*, 1999, **151**, 283–312.
  - 44 B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan and M. Karplus, CHARMM: A program for macromolecular energy, minimization, and dynamics calculations, *J. Comput. Chem.*, 1983, **4**, 187–217.
  - 45 A. D. MacKerell, M. Feig and C. L. Brooks, Improved treatment of the protein backbone in empirical force fields, *J. Am. Chem. Soc.*, 2004, **126**, 698–699.
  - 46 W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, Comparison of simple potential functions for simulating liquid water, *J. Chem. Phys.*, 1983, **79**, 926–935.
  - 47 M. W. Mahoney and W. L. Jorgensen, A five-site model for liquid water and the reproduction of the density anomaly by rigid, nonpolarizable potential functions, *J. Chem. Phys.*, 2000, **112**, 8910–8922.
  - 48 U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. Pedersen, A smooth particle mesh Ewald method, *J. Chem. Phys.*, 1995, **103**, 8577–8593.
  - 49 K. Tu, D. J. Tobias and M. L. Klein, Constant pressure and temperature molecular dynamics simulation of a fully hydrated liquid crystal phase dipalmitoylphosphatidylcholine bilayer, *Biophys. J.*, 1995, **69**, 2558–2562.
  - 50 A. D. MacKerell Jr, D. Bashford, M. Bellott, R. L. Dunbrack Jr, J. D. Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo and S. Ha, All-atom empirical potential for molecular modeling and dynamics studies of proteins, *J. Phys. Chem. B*, 1998, **102**, 3586–3616.
  - 51 P. Jungwirth and D. J. Tobias, Molecular structure of salt solutions: a new view of the interface with implications for heterogeneous atmospheric chemistry, *J. Phys. Chem. B*, 2001, **105**, 10468–10472.
  - 52 M. S. Lee, M. Feig, F. R. Salsbury and C. L. Brooks, New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations, *J. Comput. Chem.*, 2003, **24**, 1348–1356.
  - 53 M. S. Lee, F. R. Salsbury Jr and C. L. Brooks III, Novel generalized Born methods, *J. Chem. Phys.*, 2002, **116**, 10606–10614.
  - 54 K. Patel, A. Kumar and S. Durani, Analysis of the structural consensus of the zinc coordination centers of metallo-protein structures, *Biochim. Biophys. Acta*, 2007, **1774**, 1247–1253.
  - 55 I. L. Alberts, K. Nadassy and S. J. Wodak, Analysis of zinc binding sites in protein crystal structures, *Protein science: a publication of the Protein Society*, 1998, **7**, 1700–1716.
  - 56 M. Laitaoja, J. Valjakka and J. Janis, Zinc coordination spheres in protein structures, *Inorg. Chem.*, 2013, **52**, 10983–10991.
  - 57 Y. Miller, H. M. Botelho and R. Nussinov, Metal binding sites in amyloid oligomers: Complexes and mechanisms, *Coord. Chem. Rev.*, 2012, **256**, 2245–2252.
  - 58 Y. Miller, B. Ma and R. Nussinov, Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape, *Chem. Rev.*, 2010, **110**, 4820–4838.
  - 59 W. Maret, Zinc and human disease, *Met. Ions Life Sci.*, 2013, **13**, 389–414.
  - 60 J. R. Brender, U. H. Durr, D. Heyl, M. B. Budarapu and A. Ramamoorthy, Membrane fragmentation by an amyloidogenic fragment of human Islet Amyloid Polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes, *Biochim. Biophys. Acta*, 2007, **1768**, 2026–2029.



- 61 S. Gilead and E. Gazit, The role of the 14–20 domain of the islet amyloid polypeptide in amyloid formation, *Exp. Diabetes Res.*, 2008, **2008**, 256954.
- 62 E. T. Jaikaran, C. E. Higham, L. C. Serpell, J. Zurdo, M. Gross, A. Clark and P. E. Fraser, Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis, *J. Mol. Biol.*, 2001, **308**, 515–525.
- 63 D. Milardi, M. F. Sciacca, M. Pappalardo, D. M. Grasso and C. La Rosa, The role of aromatic side-chains in amyloid growth and membrane interaction of the islet amyloid polypeptide fragment LANFLVH, *Eur. Biophys. J.*, 2011, **40**, 1–12.
- 64 L. A. Scrocchi, K. Ha, Y. Chen, L. Wu, F. Wang and P. E. Fraser, Identification of minimal peptide sequences in the (8–20) domain of human islet amyloid polypeptide involved in fibrillogenesis, *J. Struct. Biol.*, 2003, **141**, 218–227.

